Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2022年6月30日
	新闻
	AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial | Reuters Reuters AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an ... 标记为不相关
	AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial | WTVB WTVB (Reuters) - Drugmaker AstraZeneca said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, ... 标记为不相关
	AstraZeneca Says Imfinzi Combo Shows Promise in Late-Stage Lung Cancer Trial USNews.com ... with neoadjuvant chemotherapy in a late-stage trial, showed promise in helping patients with an aggressive form of lung cancer before surgery. 标记为不相关
	AstraZeneca receives positive interim results from lung cancer drug trial - Sharecast.com Sharecast.com ... has received positive results from a planned interim analysis of the AEGEAN Phase III trial on its resectable non-small cell lung cancer drug. 标记为不相关
	AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial Financial Post Drugmaker AstraZeneca said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, ... 标记为不相关
	AstraZeneca: Imfinzi Plus Chemotherapy Improved PCR In Resectable Lung Cancer - Quick Facts Nasdaq ... interim analysis of the AEGEAN Phase III trial that evaluated Imfinzi (durvalumab) plus chemotherapy in resectable non-small cell lung cancer. 标记为不相关
	Existing cancer drug shows promise for treating patients with muscular dystrophy News-Medical ... an existing cancer drug could have potential as a treatment for muscular ... with the disease eventually impacting heart and lung function. 标记为不相关
	AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial Market Screener Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈